 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12345678910111213...1314» |
- |||| Darzalex (daratumumab) / J&J, Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
New P2 trial: Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. (clinicaltrials.gov) - Aug 6, 2025
P2, N=150, Not yet recruiting, Sponsor: European Myeloma Network B.V.
- || Review, Journal: Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline. (Pubmed Central) - Aug 2, 2025
Since blinatumomab's approval as the first bispecific antibody (BsAb) in cancer therapy, these immunomodulatory agents have achieved substantial success in lymphoid malignancies...In lymphoma, epcoritamab, glofitamab, and mosunetuzumab show proof-of-principle for complete remission (CR) without chemotherapy or cell-based treatment...In MM, teclistamab, talquetamab, and elranatamab achieve impressive CR rates in the relapsed setting and similarly, are being investigated in earlier line combinations and in precursor entities such as smoldering myeloma and monoclonal gammopathy of undetermined significance (MGUS). With a unique mechanism of action and continued testing in earlier lines, BsAbs are poised to be among the winners in the race to the frontline treatment of hematologic malignancies.
- ||| Journal, Adverse events: Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma. (Pubmed Central) - Aug 2, 2025
Among these, 1276 patients received BCMA BsAbs, 841 treated with GPRC5D/FcRH5 BsAbs, 157 received teclistamab + talquetamab, and 65 patients received a talquetamab + daratumumab, and 35 patients received talquetamab + pomalidomide...CRS and the need for tocilizumab were significantly less frequent with BCMA BsAbs vs GPRC5D/FcRH5 BsAbs, (P?<?0.002)...GPRC5D/FcRH5 are associated with less grade 3/4 hematologic toxicity whereas BCMA BsAbs were associated with lower grade 3/4 CRS rates, compared to GPRC5D/FcRH5. These insights are crucial for guiding treatment decisions and developing strategies to improve patient outcomes.
- | Talvey (talquetamab-tgvs) / J&J
Journal: Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy. (Pubmed Central) - Aug 1, 2025
Talquetamab correlated with sustained soluble BCMA decline and peak CAR-T expansion around day 14. Talquetamab bridging appears safe enabling the majority of difficult to treat patients to successfully proceed to BCMA CAR-T therapy.
- Talvey (talquetamab-tgvs) / J&J
Onychomadesis and palmoplantar erythema secondary to talquetamab in a patient with refractory multiple myeloma: a case report. (Poster Area) - Jul 23, 2025 - Abstract #EADV2025EADV_2143;
- | Journal: IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma regardless of IgG levels. (Pubmed Central) - Jul 21, 2025
We also discuss strategies to improve the cost-effectiveness of IVIG and SCIG across the world. Given the overwhelmingly favorable benefit-risk profile of IgRT coupled with the limitations inherent to IgG measurements in MM, withholding IgRT access based on arbitrary IgG thresholds is neither scientifically sound nor clinically appropriate for patients with MM receiving bsAb therapy.
- | Japanese regulatory, Journal: PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for hepatocellular carcinoma, fedratinib for myelofibrosis, talquetamab for multiple myeloma, and belzutifan for tumors associated with von Hippel-Lindau disease and renal cell carcinoma. (Pubmed Central) - Jul 12, 2025
Given the overwhelmingly favorable benefit-risk profile of IgRT coupled with the limitations inherent to IgG measurements in MM, withholding IgRT access based on arbitrary IgG thresholds is neither scientifically sound nor clinically appropriate for patients with MM receiving bsAb therapy. No abstract available
- || Talvey (talquetamab-tgvs) / J&J
Review, Journal: Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab: Highlights From Pharmacists' Perspectives. (Pubmed Central) - Jul 2, 2025
Adverse events were manageable and led to few treatment discontinuations. This review reports on talquetamab safety in MonumenTAL-1, with an additional pharmacy focus on strategies related to drug dispensing and clinical management.
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial completion date, Trial primary completion date, Minimal residual disease: Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) (clinicaltrials.gov) - Jun 27, 2025
P2, N=50, Not yet recruiting, Sponsor: Noffar Bar
This review reports on talquetamab safety in MonumenTAL-1, with an additional pharmacy focus on strategies related to drug dispensing and clinical management. Trial completion date: Mar 2029 --> Jun 2029 | Trial primary completion date: Mar 2029 --> Jun 2029
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Talvey (talquetamab-tgvs) / J&J
Journal: Evolving Magnetic Resonance Imaging (MRI) Findings in Immune Effector Cell-Associated Neurotoxicity Syndrome. (Pubmed Central) - Jun 20, 2025
Trial completion date: Mar 2029 --> Jun 2029 | Trial primary completion date: Mar 2029 --> Jun 2029 We present the case of a
- || Darzalex (daratumumab) / J&J, Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
New P2 trial: MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma (clinicaltrials.gov) - Jun 19, 2025
P2, N=50, Not yet recruiting, Sponsor: University of Arkansas
- Empliciti (elotuzumab) / AbbVie, BMS
Multiple Myeloma Unpacked () - Jun 16, 2025 - Abstract #ICML2025ICML_1265;
P3
Abbreviations: DRd, daratumumab-lenalidomide-dexamethasone; DVMP, daratumumab-bortezomib-melphalan-prednisone; DVRd, daratumumab-bortezomib-lenalidomide-dexamethasone; DVTd, daratumumab-bortezomib-thalidomide-dexamethasone; IsaKRd, isatuximab-carfilzomib-lenalidomide-dexamethasone; IsaVRd, isatuximab-bortzezomib-lenalidomide-dexamethasone; KRd, carfilzomib-lenalidomide-dexamethasone; Rd, lenalidomide-dexamethasone; VMP, bortezomib-melphalan-prednisone; VRd, bortezomib-lenalidomide-dexamethasone; VTd, bortezomib-talidomide-dexamethasone...Abbreviations: Bela-Vd, belantamab mafodotin-bortezomib-dexamethasone; Cilta-cel, ciltacabtagene autoleucel; DKd, daratumumab-carfilzomib-dexamethasone; DPd, daratumumab-pomalidomide-dexamethasone; DVd, daratumumab-bortezomib-dexamethasone; Erd, elotuzumab-lenalidomide-dexamethasone; Ide-cel, idecabtagene vicleucel; IV, intravenously; Kd, carfilzomib-dexamethasone; MRD, minimal residual disease; NA, not available; ORR, overall response rate; Pd, pomalidomide dexamethasone; PFS, progression-free survival; PO, by mouth; PVd, pomalidomide-bortezomib-dexamethasone; Q2W, every 2 weeks; Q4W, every 4 weeks; QW, every week; RP2D, recommended phase 2 dose; SC, subcutaneously; SVd, selinexor-bortezomib-dexamethasone; TCR, triple class refractory; Vd, bortezomib-dexamethasone; XRd, ixazomib-lenalidomide-dexamethasone...Over the past year, two recent Phase III studies, DREAMM-7 [74] and DREAMM-8 [75], have shown a significant PFS benefit of belantamab in combination with either bortezomib or pomalidomide, respectively, as a second-line or later treatment...Two BCMA-targeting bispecific antibodies, teclistamab [82] and elranatamab [78], and a bispecific antibody targeting G protein-coupled receptor class C group 5 member D (GPRC5D), Talquetamab [83] have been approved for patients triple class exposed RRMM patients from fourth line...For example, anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T therapy that incorporates a D-domain binding motif, setting it apart from traditional BCMA CAR-T therapies, which rely on single-chain variable fragments for antigen recognition...Conversely, arlocabtagene autoleucel (arlo-cel) is an anti-GPC5RD CAR-T therapy that showed an ORR of 87% and a PFS of 18.3 months [89]...A phase I/II trial of Linvoseltamab showed promising efficacy, with a 71% overall response rate (ORR) and 50% achieving complete response at the 200 mg dose...With a different target, Cevostamab, an FcRH5/CD3 bispecific antibody, has demonstrated clinical activity in heavily treated MM patients in a phase I trial [93]. Additionally, trispecific antibodies (ISB 2001
- || Abecma (idecabtagene vicleucel) / BMS
Trial completion date: KarMMa-2: An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (clinicaltrials.gov) - Jun 11, 2025
P2, N=264, Active, not recruiting, Sponsor: Celgene
Additionally, trispecific antibodies (ISB 2001 Trial completion date: Dec 2030 --> Oct 2025
- | Talvey (talquetamab-tgvs) / J&J
Journal: EDE and EDE-Q: A Call for Field Wide International Collaboration When Revisiting a Classic, Commentary on Reilly et (Pubmed Central) - Jun 5, 2025
Trial completion date: Dec 2030 --> Oct 2025 In their 2025 article in the International Journal of Eating Disorders, Reilly, Gorrell, Chapa, Drury, Stalvey, Goldschmidt, and le Grange examine the widespread use of the Eating Disorder Examination (EDE) and its self-report version, the Eating Disorder Examination-Questionnaire (EDE-Q), in assessing eating disorder symptoms...Reilly et
- || Tecvayli (teclistamab-cqyv) / Genmab, J&J
New P2 trial, Minimal residual disease: Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) (clinicaltrials.gov) - May 30, 2025
P2, N=50, Not yet recruiting, Sponsor: Noffar Bar
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
New P2 trial: A Centralized Platform study for Functional High Risk Multiple Myeloma: Domain 1 (EUDRACT) - May 16, 2025
P2, N=20, Not yet recruiting, Sponsor: Australasian Myeloma Research Consortium
- Talvey (talquetamab-tgvs) / J&J
EFFICACY AND SAFETY OF TALQUETAMAB AMONG HEAVILY PRE-TREATED PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA IN THE EXPANDED ACCESS PROGRAM AND COMMERCIAL SETTING () - May 15, 2025 - Abstract #EHA2025EHA_4301;
While the ORR (70%) was similar to that in TAL-1, DoR and PFS were shorter than those observed in TAL-1 pts who were less pre-treated and had not received prior BCMA CAR-T or BsAb. High percentage of pts exposed to prior BsAb may have impacted DoR and PFS, as observed in the trial.
- SYSTEMATIC REVIEW OF BISPECIFIC ANTIBODIES EFFICACY AND SAFETY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA () - May 15, 2025 - Abstract #EHA2025EHA_4160;
Currently, three BsAbs - teclistamab (MajesTEC-1), talquetamab (MonumenTAL-1), and elranatamab (MagnetisMM-3)- have received accelerated FDA approval. However, BsAbs are associated with safety concerns, including cytokine release syndrome, hematologic toxicity, and an increased risk of infections.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN A MULTIPLE MYELOMA PATIENT TREATED WITH TECLISTAMAB AND TALQUETAMAB. () - May 15, 2025 - Abstract #EHA2025EHA_4024;
Emerging data suggest an increased risk of PML in this population. Clinicians should consider PML as a differential diagnosis in patients receiving BCMA-targeted treatments who present with unexplained neurological symptoms.
- BCMA-TARGETING T-CELL REDIRECTING BISPECIFIC ANTIBODY THERAPY POST-GPRC5D-DIRECTED BISPECIFIC ANTIBODY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (IFM 2024-13 BCMA POST-GPRC5D) (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_3190;
No additional toxicities were observed. For responding patients, PFS was prolonged and for pts na
- Talvey (talquetamab-tgvs) / J&J
UPDATED COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN'S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_3181;
P, P1, P2
For responding patients, PFS was prolonged and for pts na With longer follow-up, Tal QW and Q2W dosing schedules continued to show superior efficacy vs RWPC, demonstrating its clinical benefit in pts with TCE RRMM.
- Talvey (talquetamab-tgvs) / J&J
PROPHYLACTIC TOCILIZUMAB TO MITIGATE CYTOKINE RELEASE SYNDROME AND OUTPATIENT DOSING OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1/2 MONUMENTAL-1 RESULTS (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_3168;
P2
No increased neutropenia or infection rates were observed. ORR was similar to the overall MonumenTAL-1 population.
- Talvey (talquetamab-tgvs) / J&J
OUTPATIENT STEP-UP DOSING AND SAFETY WITH TALQUETAMAB: A REAL-WORLD MAYO CLINIC STUDY (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_3166;
Patients receiving talquetamab SUD in the outpatient setting had few admissions on average with a short total LOS while maintaining a similar CRS profile to that previously shown for talquetamab. While further real-world research will provide additional insights into long-term talquetamab dosing in various settings, data from this study support the feasibility of outpatient talquetamab SUD administration.
- Talvey (talquetamab-tgvs) / J&J
REAL-WORLD ANALYSIS OF TALQUETAMAB IN HEAVILY PRETREATED AND HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_3164;
Most pts also had aggressive disease biology with 88% having at least 1 ?HRCA, EMD, and/or cPCs. Tal resulted in ORR of 47% and mPFS of 6.2 mos.
- Talvey (talquetamab-tgvs) / J&J
TALQUETAMAB VS REAL-WORLD PHYSICIAN'S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN THERAPY: UPDATED ANALYSES OF MONUMENTAL-1 VS LOCOMMOTION/MOMMENT (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_3131;
P, P1, P2
Tal resulted in ORR of 47% and mPFS of 6.2 mos. With longer follow-up, Tal continued to demonstrate superior efficacy vs RWPC in pts with TCE RRMM and prior BCMA TCR exposure, further supporting Tal as an effective treatment option in this pt population.
- Elrexfio (elranatamab-bcmm) / Pfizer, Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
IMMUNOMMAP: INSIGHTS INTO IMMUNE AND GENOMIC ALTERATIONS UNDERLYING THE RESISTANCE TO BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA BY FULL SPECTRUM CYTOMETRY AND EXOME SEQUENCING (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_3104;
Early T-cell depletion and key tumor mutations suggest aggressive disease and therapy failure. These findings emphasize the value of integrating immune and genomic profiling to predict resistance and guide therapy, warranting further validation.
- EPIGENETIC DRIVERS OF IMMUNOTHERAPY RESISTANCE IN MULTIPLE MYELOMA: ADVANCED MULTI-OMIC PROFILING IDENTIFIES BCMA AND FCRL5 SILENCING VIA LONG-RANGE DNA HYPERMETHYLATION (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_3103;
In this case, no CNVs or SNVs were detected, implicating epigenetic silencing as the only cause. Moreover, the persistence of an epigenetic memory of previous therapies suggests DNA methylation as a potential biomarker of treatment history.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
IMAGE-BASED EX-VIVO IMMUNOTHERAPY SCREENING ASSAY PREDICTS RESPONSE TO BISPECIFIC T CELL ENGAGERS IN MULTIPLE MYELOMA PATIENTS (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_3096;
Mononuclear bone marrow cells were freshly isolated from MM patients (n = 31) followed by ex vivo treatment with Teclistamab and Talquetamab. Our findings highlight the value of an image-based immunotherapy screening assay by capturing the heterogeneity of T cell-mediated responses to BiTE therapy in MM and suggest that variations in T cell response dynamics may serve as a functional biomarker for clinical response, paving the way for improved patient stratification and treatment optimization.
- Elrexfio (elranatamab-bcmm) / Pfizer, Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
SELECTIVE DEPLETION OF B-CELL LINEAGE SUBSETS DURING TREATMENT WITH ANTI-BCMA VS ANTI-GPRC5D BISPECIFIC ANTIBODIES (BSABS) UNDERLIES DIFFERENT RISK OF INFECTIONS IN PATIENTS WITH MULTIPLE MYELOMA (MM) (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_3079;
Distinct patterns of BCMA and GPRC5D expression throughout the B cell lineage explain different on-target off-tumor effects, which leads to the depletion of mature B cells, normal PCs and subset of B cell precursors with anti-BCMA bsAbs. These findings may help the management of bsAbs treated patients such as individualized use of IVIG prophylaxis.
- Talvey (talquetamab-tgvs) / J&J
TALQUETAMAB + CETRELIMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 1B TRIMM-3 STUDY (Auditorium) - May 15, 2025 - Abstract #EHA2025EHA_2473;
P1
Tal + Cet showed deep and durable responses in pts with RRMM and prior CD3 redirecting Ab therapy, contrary to results with Tal monotherapy (shortened durability) but similar to results with Tal + daratumumab. These proof-of-concept data are encouraging for PD-1 inhibition in RRMM and further support Tal as a versatile combination partner to overcome intrinsic resistance mechanisms due to its unique mechanism of action.
- Talvey (talquetamab-tgvs) / J&J
TALQUETAMAB IMMUNOGENICITY AND IMPACT ON EXPOSURE, EFFICACY, AND SAFETY: ANALYSES FROM PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN MONUMENTAL-1 (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_2150;
This abstract is embargoed until May 22, 2025 (23:00 CEST), until publication by the American Society of Clinical Oncology, Inc. for their 2025 ASCO Annual Meeting.This abstract is embargoed until Thursday, June 12, 2025, 08:00 CEST.Presentation during EHA2025: All (e)Poster presentations will be made available as of Thursday, June 12, 2025 (08:00 CEST) will be accessible for on-demand viewing from June 18 to August 15, 2025 on the Congress platform.
- Talvey (talquetamab-tgvs) / J&J
RETROSPECTIVE STUDY TO DESCRIBE THE CLINICAL CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF TALQUETAMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA TREATED OUTSIDE CLINICAL TRIALS IN SPAIN. (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_2133;
The BiTAL study may represent one of the largest single-country cohorts of RRMM TCE pts treated with TAL outside registrational clinical trials. In this initial analysis focusing on pts characteristics and treatment effectiveness, the results obtained highlighted the heterogeneity of RRMM in a setting comparable to real-world conditions, and the effectiveness outcomes observed thus far appeared to align with those reported in the MonumenTAL-1 trial.
- Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J, Blenrep (belantamab mafodotin-blmf) / GSK
REAL-WORLD EFFECTIVENESS OF BELANTAMAB MAFODOTIN, BCMA-CD3 BISPECIFIC ANTIBODIES AND TALQUETAMAB IN PATIENTS WITH TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA. FIRST RESULTS FROM THE DANISH ABCD-STUDY. (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_2122;
We found that class-specific AEs for each respective drug were a frequent cause for reductions of dose and dose intensity. The retrospective nature, heterogeneous population and sample-size can explain the differences in effectiveness in our cohort compared to prospective clinical studies.
- Talvey (talquetamab-tgvs) / J&J
REAL-WORLD CHARACTERISTICS AND SAFETY AND EFFECTIVENESS OF TALQUETAMAB AMONG PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN ELECTRONIC MEDICAL RECORD AND CHART REVIEW STUDY (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_2120;
Majority of CRS events were mild and majority of pts with dysgeusia reported an improvement. Overall, these findings support the use of TAL as an effective treatment for pts with RRMM.
- Talvey (talquetamab-tgvs) / J&J
FIRST RESULTS FROM REALITAL: A EUROPEAN MULTI-COUNTRY OBSERVATIONAL RETROSPECTIVE STUDY OF TALQUETAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_2103;
These results are comparable to MonumenTAL-1 results in terms of the activity and tolerability of talquetamab especially considering this hard-to-treat heavily pre-treated patient population in this study. The results also align with previous findings, where achieving a deep response with talquetamab was linked to prolonged DoR, PFS, and OS.
- Talvey (talquetamab-tgvs) / J&J
EXPLORATORY BIOMARKERS ASSOCIATED WITH TALQUETAMAB RESISTANCE AND RELAPSE IN THE MONUMENTAL-1 CHINA 400 COHORT BY DATA-DRIVEN UNSUPERVISED CLUSTERING ANALYSIS (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_2064;
P1, P2
These findings suggest that T cell exhaustion was associated with Tal resistance and relapse and support a combination strategy with other drugs (e.g. Dara). The unsupervised clustering approach identified distinct T cell populations which were not captured by conventional gating, highlighting its value as a complementary method for flow cytometry data analysis.
- Darzalex (daratumumab) / J&J, Carvykti (ciltacabtagene autoleucel) / J&J
PRECLINICAL ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMBINATION STRATEGIES WITH T CELL BISPECIFICS AND DARATUMUMAB TO SUPPORT OPTIMIZATION OF CLINICAL BENEFIT IN MYELOMA PATIENTS (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_2053;
They also suggest that Tec, Tal and Dara, may have an important role in bridging and maintenance strategies to enhance the cytotoxic activity of Cilta-cel, if labeling indications permit. Furthermore, these agents may potentially optimize reduced Cilta-cel cytotoxicity resulting from previous BsAb exposure.
- MASS SPECTROMETRY ENABLES PRECISE MONITORING OF BISPECIFIC ANTIBODY THERAPY IN MULTIPLE MYELOMA (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_2049;
In addition, only one patient relapsed during the follow-up. MS enables accurate identification of bispecific antibodies in serum samples, ensuring no interference with MP quantification.
- Elrexfio (elranatamab-bcmm) / Pfizer, Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
MULTI-OMICS ARCHITECTURE OF PLASMABLASTIC LYMPHOMA: EBV-MEDIATED AND GENOTYPE-SPECIFIC EFFECTS ON THE TUMOR MICROENVIRONMENT AND THERAPEUTIC VULNERABILITIES (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_1930;
This work highlights promising strategies for targeted treatment in PBL and potentially other lymphoma subtypes with similar pathogenic mechanisms. Currently efforts are underway to further enhance cellular cytotoxicity through hypothesis-driven screens for synthetic lethality, informed by genomic and particularly transcriptional data from our single-cell RNA-sequencing experiments in both EBV-positive and -negative cohorts.
- | Journal: Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting. (Pubmed Central) - May 14, 2025
Furthermore, a more simplified myeloma response assessment may be feasible. Overall, we provide a critical summary of key studies on MM from the last ASH meeting.
- | Journal: Using bispecific antibodies in a patient with peritoneal dialysis for relapsed multiple myeloma. (Pubmed Central) - May 13, 2025
Following relapse, she was transitioned to elotuzumab, pomalidomide, and dexamethasone, then selinexor as a bridge to chimeric antigen receptor T-cell (CAR-T) therapy.DiscussionThis case demonstrates that BsAbs may be effective in RRMM patients on PD, though responses were transient. Further research is needed to explore BsAbs' pharmacokinetics, optimal dosing, and long-term outcomes in dialysis-dependent MM patients.
- || Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Trial completion date, Trial primary completion date: OPTec: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (clinicaltrials.gov) - May 12, 2025
P2, N=75, Recruiting, Sponsor: SCRI Development Innovations, LLC
Further research is needed to explore BsAbs' pharmacokinetics, optimal dosing, and long-term outcomes in dialysis-dependent MM patients. Trial completion date: Aug 2025 --> Mar 2026 | Trial primary completion date: Jul 2025 --> Feb 2026
- || Talvey (talquetamab-tgvs) / J&J
P1 data, Journal: Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM. (Pubmed Central) - May 9, 2025
With an overall median follow-up of 9.0 months, the ORR was 60.0% (95% confidence interval 32.3%, 83.7%). Talquetamab showed substantial responses in Japanese patients with RRMM, consistent with the global MonumenTAL-1 study, supporting its potential as a new standard of care for Japanese RRMM patients.
- COMBINING BISPECIFICS AND RADIATION FOR REL/REF HEMATOLOGIC MALIGNANCIES: FRIEND OR FOE? (Exhibition Area) - May 4, 2025 - Abstract #ICML2025ICML_833;
We report our early experience using RT in combination with BsAbs, highlighting its safety, feasibility, and excellent local control rates, even in bulky sites. Longer follow-up with larger cohorts is needed to assess the durability of response and the dose-response relationship.
- DEVELOPING AN OUTPATIENT BISPECIFIC ANTIBODY THERAPY PROGRAM: INFRASTRUCTURE AND TOOLS FROM THE JOHNS HOPKINS SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER () - May 4, 2025 - Abstract #ICML2025ICML_578;
No higher grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. In patients receiving epcoritamab, maximum grade CRS experienced by patients was 1, 2, 3, and 4 in 3 (14%), 6 (28%), 1 (5%), and 1 (5%) of patients, respectively.
- Talvey (talquetamab-tgvs) / J&J
Recurrence of Multiple Myeloma Presenting as a Thyroid Plasmacytoma in a Patient with Long-standing Thyroid Nodules (ENDOExpo: Poster Area) - Apr 27, 2025 - Abstract #ENDO2025ENDO_2696;
She then underwent interval treatment with Talquetamab, with resolution of metabolic activity in the thyroid.Discussion MM accounts for 80% of plasma cell malignancies, characterized by deposition of neoplastic plasma cells in the bone marrow as well as extramedullary sites (plasmacytoma)...A combination of both local disease control and systemic treatment of MM is required for remission. Our case highlights a rare endocrine complication of a well-known malignancy.
- || Talvey (talquetamab-tgvs) / J&J
Trial completion date: TALMMY1001-PT3: A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 26, 2025
P2, N=510, Recruiting, Sponsor: Janssen Research & Development, LLC
Our case highlights a rare endocrine complication of a well-known malignancy. Trial completion date: Mar 2027 --> Mar 2029
- | Talvey (talquetamab-tgvs) / J&J
Trial completion date: MonumenTAL-1: Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 26, 2025
P1, N=279, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Mar 2027 --> Mar 2029 Trial completion date: Mar 2027 --> Mar 2029
- Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
B-cell maturation antigen (BCMA) immunohistochemistry (IHC) staining in multiple myeloma (MM) patients with prior use of BCMA-based therapies. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6268;
Routine BCMA IHC testing maybe needed before initiating additional BCMA-targeted therapies to better guide treatment decisions. Notably, patients without prior BCMA exposure retain BCMA expression, indicating potential benefit from BCMA-targeted therapies in this group.
- Elrexfio (elranatamab-bcmm) / Pfizer, Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Infectious complications in relapsed/refractory multiple myeloma patients treated with bispecific antibodies: Meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_6266;
While these therapeutic modalities demonstrate promising efficacy, oncologists, infectious disease physicians, and pharmacists need awareness of potential toxicities to establish strategies for infectious disease prevention and management to provide quality care. Infection related complications of teclistamab, talquetamab, and elranatamab, abridged.